Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — The Biden administration on Friday proposed the creation of a $6.5 billion medical research agency with an audacious goal: quickly developing cures for diseases including cancer, Alzheimer’s, and diabetes.

If the agency is established, it could mark a fundamental shift in how the U.S. government funds research, steering the emphasis from basic science to higher-risk projects more directly aimed at major medical breakthroughs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • But DEAD HEAD JOE already cured cancer with his MOONSHOT program which was launched in January 2016 (after being VP for over 7 years) to distract attention from the failing Obama care. Another publicity stunt but not a cheap one for taxpayers

  • So NIH is to large, too slow, and too conservative

    So put a new 6.5 billion dollar agency INSIDE NIH?

    Better yet: give more grant money, scored grants acceptable or not acceptable, then randomly grant research dollars to the “acceptables”. You’ll see new ideas tried and more young researchers get money.

  • This is a great idea — as long as the government acts as a fiduciary for taxpayers and not a free cash machine for private sector companies when it invests in the high-risk clinical and manufacturing development.

Comments are closed.